In an interesting paper Milionis et al. [1], aimed to investigate the effect of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibition on stroke risk in a meta-analysis involving data from randomized studies with alirocumab and evolocumab. Though PCSK9 inhibition showed no significant effect on stroke rate, mainly because the number of patients having an ischemic stroke was small in the included trials, it's clear that we are witnessing the birth of a new era in stroke prevention.
